×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Fact or Fiction: Patient Engagement in the Drug Development Process
Session Chair(s)
Robert Paarlberg, MS
Principal
Paarlberg & Associates LLC, United States
Industry Perspective
Learning Objective : Describe benefits of engaging patient and patient advocacy groups in the drug development process; Discuss regulatory agency experiences with including patient and patient advocacy groups in the decision-making process.
Speaker(s)
Industry Perspective
Michael Maher
Pfizer Inc, United States
Executive Director, US Regulatory Policy and Global Intelligence
FDA Perspective
John Whyte, DrMed, MD, MPH
WebMD, United States
Chief Medical Officer
Patient Perspective
Marcia K. Horn, JD
ICAN, International Cancer Advocacy Network, United States
President and CEO
Have an account?